On August 29, Kedeb - B (02487.HK) announced that the results of the Phase III clinical trial of CU-40102 (topical finasteride spray) for the treatment of androgenetic alopecia were accepted and presented in the form of an e-poster at the 8th China Congress of Hair Research, hosted by the Chinese Medical Association.

CU-40102 is the first and only topical finasteride product approved for the treatment of androgenetic alopecia worldwide. It is also the first topical finasteride product to be accepted by the National Medical Products Administration (NMPA) in China for new drug application (NDA). The Phase III registration clinical trial of CU-40102 in China is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of CU-40102 in Chinese adult male patients with androgenetic alopecia.